- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04622605
Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma
Study Overview
Status
Intervention / Treatment
Detailed Description
The objective of this study is to assess the effectiveness of the Hydrus Microstent for lowering intraocular pressure in patients with PAC or PACG. The addition of the Hydrus is expected to lower IOP and medication dependency, and thus reduce the risk of progression of glaucoma. The PCS group will provide a control group to assess the magnitude of the Hydrus treatment effect on IOP, medications, and safety.
Upon successfully meeting the study inclusion/exclusion criteria at both the screening and baseline visits, the subject will be scheduled for surgery. Follow up will be continued for 1 year post surgery, and will include assessments of the subject's IOP, ocular health, and visual acuity status. Visits will be conducted at 1, 7, 30, 90, 180, and 365 days.
A 20% drop in IOP in response to therapy is considered clinically meaningful. The study treatment will be considered successful if a patient can obtain this response in IOP using the same or a fewer number of medications as pre-operative baseline.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Metro Manila
-
Makati City, Metro Manila, Philippines, 1200
- Asian Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pre-Operative Inclusion Criteria
- Male and Female patients at least 40 years of age.
- An operable age-related cataract with visual impairment or glare, eligible for phacoemulsification.
- Subjects with diagnosed primary angle-closure (PAC; defined as appositional or synechial irido-trabecular contact of 90 degrees or more on gonionscopy) OR primary angle-closure glaucoma (PACG; defined as PAC with documented glaucomatous optic neuropathy and/or reproducible glaucomatous visual field defect), and on > or = 1 glaucoma medication with IOP > or = 21mmHg at both preoperative visits.
- PAC or PACG subjects that are newly diagnosed, or unmedicated (newly diagnosed or non-compliant patient not using medication for > 30 days), with IOP > or = 24mmHg at both preoperative visits.
The subject is able to understand the requirements of the study and is willing to provide written informed consent, follow study instructions, and comply with all study procedures.
Intraoperative Inclusion Critera
- An intact and centered capsulorhexis.
- An intact posterior capsular bag.
- A well-centered IOL implant placed in the capsular bag.
- A clear view and visualization of the angle with direct gonioscopy.
- No evidence of zonular dehiscence/rupture (uncomplicated cataract extraction)
Exclusion Criteria:
- Pseudophakia in the intended study eye
- All forms of glaucoma other than primary angle-closure (i.e. all open-angle glaucoma including primary open-angle, pseudoexfoliative, or pigmentary glaucoma; neovascular, uveitic, traumatic, steroid induced, lens induced, or glaucoma associated with increased episcleral venous pressure; congenital or developmental glaucoma).
- Secondary angle-closure glaucoma
- Advanced glaucoma, defined as visual field mean deviation worse than -15 dB, or cup-to-disc ration > or = 0.9.
- Visual field depression within the central 5 degrees of fixation, on pattern deviation probability plot.
- Eyes with an anticipated need for incisional glaucoma surgery (e.g. trabeculectomy or tube shunt) within the 12-month follow-up period.
- Central corneal thickness >620 or <490 microns.
- Axial length < or = 19 mm (nanophthalmos).
- Previous incisional glaucoma surgery in the study eye, including trabeculectomy, tube shunt, and non-penetrating procedures such as deep sclerectomy, viscocanalostomy or canaloplasty.
- Plateau iris syndrome.
- History of complicated intraocular surgery.
- Previous MIGS surgery in the study eye.
- Proliferative diabetic retinopathy.
- Previous surgery for retinal detachment.
- Clinically significant corneal dystrophy (e.g. Fuch's Dystrophy).
- Best-corrected visual acuity in the fellow eye worse than 20/200.
- Previous corneal surgery.
- Previous refractive surgery.
- Degenerative visual disorders such as exudative age-related macular degeneration.
- Clinically significant ocular inflammation or infection within thirty days prior to screening.
- Uncontrolled systemic disease that in the opinion of the investigator would put the subject's health at risk and/or prevent the subject from completing all study visits.
- Pregnant or nursing females.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group
Cataract extraction and intraocular lens placement with combined placement of glaucoma microstent
|
ab interno Microstent placement after cataract surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in IOP
Time Frame: 12 months
|
Proportion of subjects with > or = 20% reduction of IOP while maintaining the same or fewer number of glaucoma medications compared with baseline, measured by Goldmann applanation tonometry
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in IOP
Time Frame: 12 months
|
Change in IOP compared to baseline IOP regardless of the number of glaucoma medications
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Angle Closure Glaucoma
-
Khoo Teck Puat HospitalCompletedPrimary Angle-Closure Glaucoma | Primary Angle Closure Without Glaucoma DamageSingapore
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
National University Hospital, SingaporeCompletedChronic Angle Closure Glaucoma | Primary Angle Closure | Primary Angle Closure Suspect | Fellow Eyes of Acute Angle Closure GlaucomaSingapore
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruitingPrimary Angle-Closure Glaucoma
-
Guy's and St Thomas' NHS Foundation TrustCompleted
-
Guangfu DangCompletedPrimary Angle Closure GlaucomaChina
-
Santen Pharma Malaysia Sdn BhdUnknownOcular Hypertension | Primary Open-angle Glaucoma | Pseudoexfoliation Glaucoma | Pigment Dispersion Glaucoma | Primary Angle-Closure Glaucoma
-
Taipei Medical University WanFang HospitalCompletedGlaucoma | Acute Primary Angle-closure GlaucomaTaiwan
-
Ulucanlar Eye Training and Research HospitalCompletedAcute Primary Angle-closure GlaucomaTurkey
-
Mansoura UniversityCompletedNarrow-Angle GlaucomaEgypt
Clinical Trials on Trabecular bypass and Schlemm's canal stent
-
Glaukos CorporationCompletedGlaucoma | Glaucoma, Open-Angle | Eye DiseasesSpain, France, Armenia, Germany, Austria, Italy
-
University of Turin, ItalyCompletedPrimary Open Angle Glaucoma and Cataracts
-
New World Medical, Inc.CompletedOpen Angle GlaucomaUnited States
-
Glaukos CorporationActive, not recruiting
-
Helsinki University Central HospitalRecruitingCataract | Exfoliation GlaucomaFinland
-
Glaukos CorporationCompletedOpen Angle GlaucomaArmenia
-
Kuopio University HospitalTurku University Hospital; Helsinki University Central Hospital; Oulu University... and other collaboratorsRecruitingClaudication | Chronic Lower Limb Ischemia | Critical Ischemia | Peripheral Athero Obstructive DiseaseFinland
-
Johns Hopkins UniversityCompletedSuperficial Femoral Artery Occlusion | Claudication | Superficial Femoral Artery Stenosis | Rest PainUnited States
-
Umeå UniversityActive, not recruitingCataract | Open Angle Glaucoma | MIGS | Kahook Dual Blade Glide | Istent Inject W | GoniotomySweden
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompletedMultivessel Coronary Artery DiseaseThailand, Korea, Republic of, China, Malaysia